Association of concomitant H1 antihistamine and immune checkpoint inhibitor therapy on survival outcome and safety in patients with advanced primary lung cancer: a cohort study
Concomitant use of H1 antihistamines can improve immunotherapy efficacy and reduce irAEs. Meanwhile, concomitant use of H2 antihistamines is associated with reduced PFS and OS time.
Authors
- Shibo Li (ORCID: https://orcid.org/0000-0002-6767-1613)
- Yoshinobu Ichiki (ORCID: https://orcid.org/0000-0002-1293-6952)
- Xiao Yu Tian (ORCID: https://orcid.org/0000-0003-3472-9898)
- Shui Cao
- Wei‐Hong Zhang (ORCID: https://orcid.org/0000-0003-0380-770X)
- Meng Shen (ORCID: https://orcid.org/0000-0002-1867-0972)
- Fan Yang (ORCID: https://orcid.org/0000-0001-5718-9420)
- Weijiao Du (ORCID: https://orcid.org/0000-0003-2267-2644)
- Zhenzhen Hui
- Yan-Juan Xiong (ORCID: https://orcid.org/0009-0000-2408-0808)
- Liping Zhou (ORCID: https://orcid.org/0000-0002-3332-2343)
- Liang Liu (ORCID: https://orcid.org/0000-0001-8630-7430)
- Xiubao Ren (ORCID: https://orcid.org/0000-0003-4137-2049)
- Xinwei Zhang (ORCID: https://orcid.org/0000-0002-1267-5182)
- Sang Chul Lee (ORCID: https://orcid.org/0000-0001-5318-6804)
- Jiali Zhang (ORCID: https://orcid.org/0009-0005-7478-8982)
- Ying Han (ORCID: https://orcid.org/0000-0002-6176-7526)
- Bingxue Li (ORCID: https://orcid.org/0009-0008-6313-2138)
- Caihong Ma (ORCID: https://orcid.org/0000-0003-0439-9621)
- Run-Mei Li
- Bao-Zhu Ren
- Jian Wang (ORCID: https://orcid.org/0009-0004-4420-1928)
Institutions
- National Health Insurance Service Ilsan Hospital (KR)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2024-10-01
- DOI
- https://doi.org/10.21037/tlcr-24-795
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- National Natural Science Foundation of China